14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
EHC vs UHS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Universal Health Services, Inc. Class B (UHS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas UHS carries 45.6/100 (HOLD) at $179.43 (7.8x Forward P/E, 10.8% operating margin).
Competes within the Medical Care Facilities value chain with $13.0B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment25.7% of Rev ($1.63B)
90D Engineering Disclosures0 Published
UHS Moat ProfileScale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $10.1B market capitalization and 10.8% operating margin.
OpEx & R&D Reinvestment33.7% of Rev ($6.18B)
90D Engineering Disclosures0 Published
Investor FAQ EHC vs UHS Key Questions & Quantitative Answers
As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Universal Health Services, Inc. Class B (UHS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas UHS carries 45.6/100 (HOLD) at $179.43 (7.8x Forward P/E, 10.8% operating margin). Technically, EHC sits in a Neutral phase (RSI 49.8, CONSOLIDATION options structure) and UHS sits in a Neutral phase (RSI 43.7, CONSOLIDATION options structure).
EHC leads the Growth & Scale pillar: EHC posts +8.9% YoY revenue growth and +21.6% YoY earnings growth on $6.34B TTM revenue (44.1% gross margin, 18.4% operating margin), compared with UHS at +5.3% YoY revenue growth and -10.9% YoY earnings growth on $18.4B TTM revenue (44.5% gross margin, 10.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EHC cumulative revenue shifted +38.8% while UHS shifted +61.2%. In operating R&D and SG&A reinvestment, EHC deploys 25.7% of Rev ($1.63B) (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($6.18B) (0 disclosures) for UHS.
UHS screens cheaper on headline valuation multiples. EHC trades at 19.4x Forward P/E, 21.2x Trailing P/E, 0.41x PEG, and 2.5x EV/Revenue (7.2% FCF margin), whereas UHS trades at 7.8x Forward P/E, 7.3x Trailing P/E, 1.41x PEG, and 0.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EHC (25.1% ROE) versus UHS (19.7% ROE) capital efficiency.
In options market volatility and institutional positioning, EHC carries 27.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.10β · 40% Vol realized risk). By comparison, UHS carries 83.7% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.09β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.